Samaritan's European Pharmaceutical Marketing Arm Gains Recognition Panel Organized by Greek Ministry of Health and the Greek Alliance of Rare Diseases
LAS VEGAS, Feb. 28, 2008 (PRIME NEWSWIRE) -- Samaritan Pharmaceuticals (OTCBB:SPHC), a biopharmaceutical company committed to commercializing new innovative therapeutic drugs, is pleased to announce its Managing Director of Europe, Dr. Christos Dakas, has been invited to speak on a press conference panel organized jointly by the Greek Ministry of Health and the Greek Alliance of Rare Diseases on Friday, February 29th.
The focus of the conference is to raise awareness of the public at large for Rare and Orphan Diseases, and in celebration of the 1st European Rare Disease Day (www.rarediseaseday.org).
Other speakers on the press conference panel include:
* Mrs. Marianna Lamprou, President of Greek Alliance of Rare Diseases
* Mr. Vasilios Kontozamanis, President of EOF (National Organization
of Medicines)
* Mr. Panagiotis Bratsos, Managing Director of IPRT (Institute of
Pharmaceutical Research and Technology)
Dr. Janet Greeson, Chief Executive Officer of Samaritan, stated, "This is a reflection of Dr. Dakas' dedication to get life-saving drugs to children suffering with rare diseases and his success in bringing medicines aimed at rare and orphan diseases to Greece and Eastern Europe. Through Samaritan's efforts, patients and families now have access to new therapies for rare diseases, which is normally an underserviced segment of the population of the country."
About Samaritan Pharmaceuticals: "Transforming Today's Science Into Tomorrow's Cures..."
Samaritan Pharmaceuticals is an entrepreneurial biopharmaceutical company committed to bringing innovative life-saving drugs to suffering patients.
For more information, please visit Samaritan's website: http://www.samaritanpharma.com. Please register so we can notify you of upcoming conference calls, news and events.
The Samaritan Pharmaceuticals Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=2670
Disclaimer
The company disclaims any information created by an outside party and endorses only information communicated by its press releases, filings, and website. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science, and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-Q filed November 19, 2007. The company undertakes no duty to update forward-looking statements.